EBS

#3040
Emergent BioSolutions Inc. Common Stock
8.3 0 USD
-0.12%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
8.26
8.32
Year Range
7.56
11.46
Daily Change
-0.12%
Monthly Change
-0.48%
6 month change
-22.57%
Year Change
-22.57%
Previous Close
8.3 1
Open
8.2 7
Low
8.2 6
High
8.3 2
Volume
583
Open full chart

Financials

Overview Statement Statistics
Quarterly Annual
  • Market Capitalization 428.25 M
  • Employee 900
  • Founded 1998
  • CEO Robert G. Kramer Sr. | Joseph C. Papa
  • Website www.emergentbiosolutions.com
  • Headquarter Delaware, United States
  • FIGI BBG000GW06J7
  • Industry Drug Manufacturers—Specialty & Generic
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-43.68
Price to sales ratio
0.69

Emergent BioSolutions Inc. Common Stock

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.

News